Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

FDA sets August review date for Teva’s movement disorder drug

Could be first approved treatment for tardive dyskinesia

- PMLiVE

Artificial intelligence: could pharma lead the way?

Producing powerful, relevant user experiences will be one key area to target

- PMLiVE

Cuttsy+Cuttsy boosts health comms team

Charlotte Diggins joins while Jill Bradshaw and Dr Liz Walder take on new roles

- PMLiVE

Bayer: Post-truth politics severely handicaps innovation

And firm also voices its concerns over Brexit

MIT chief financial officer joins Moderna Therapeutics

Israel Ruiz to serve as audit committee chair on its board of directors

- PMLiVE

La Jolla plans filing on back of blood pressure trial data

Almost three-quarters of CRH patients met threshold for blood pressure response

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

- PMLiVE

Keeping it in the family pays dividends

How playing the long game works for family-held and foundation firms through boom and bust

- PMLiVE

Celgene’s president and COO to retire

Scott Smith set to succeed Dr Jacqualyn Fouse from 1 April

- PMLiVE

Pfizer strengthens board of directors

Ronald Blaylock brings financial and business leadership expertise

Two ‘must haves’ for multichannel success

What do great multichannel projects have in common? At a recent Anthill webinar, speakers highlighted two essentials for multichannel success.

Anthill Agency

We’re celebrating 10 years of changing lives with medical education

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links